FDA warns Shuzy Rock Inc. of adulterated hand sanitizers made under insanitary conditions and found below labeled alcohol strength.
What happened
FDA inspected Shuzy Rock's South Plainfield, NJ drug manufacturing facility from January 11 to February 14, 2022. Investigators found insanitary conditions, inadequate cleaning and water controls, no functioning quality unit, and no release testing. FDA lab testing of U.S. market hand sanitizer batches found ethanol at 48–57% instead of labeled 65%, and 55% instead of 70%.
What FDA found
The company made drugs under insanitary conditions, with refuse, spills, broken tiles, soiled equipment, and inadequate cleaning.
FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)The company's hand sanitizer was subpotent: batches labeled 65% ethanol contained 48–57%, and a batch labeled 70% contained 55%.
FD&C Act section 501(c), 21 U.S.C. 351(c)The company lacked a functioning quality control unit to approve or reject materials and products, investigate problems, and handle complaints or recalls.
21 CFR 211.22The company lacked adequate written production and process controls, including critical manufacturing parameters and executed batch records for distributed hand sanitizer.
21 CFR 211.100(a)The company did not perform adequate laboratory testing before releasing batches to confirm identity and strength, and could not provide release test results.
21 CFR 211.165(a)The company did not register its establishment or list its drug products with FDA.
FD&C Act section 510, 21 U.S.C. 360; 21 CFR 207.17(a), 207.41
What FDA wants
FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, investigations, batch records, and remediation plans. If the company resumes drug manufacturing, FDA says it must notify the office first and engage a qualified CGMP consultant.
Who should pay attention
- brands or distributors that sold Premium Nature hand sanitizer
- contract manufacturers and repackers of OTC drugs or cosmetics
- companies relying on supplier CGMP and FDA registration/listing status
This is a summary. Read the original letter on fda.gov.